CD274 and neoplasm: Although both of the previous categories (i.e., PDACs with upregulation of PD-L1 and PDACs with MMR deficiency) could represent good candidates for the administration of checkpoint blockade therapy, the low frequency of these tumours might explain the limited success of this treatment modality in PDAC.